ION775 - LARVOL DELTA

…Ionis will share positive interim Phase 1 results of ION775, an apoC-III siRNA with the potential for semiannual dosing and Ionis’ first clinical-stage siRNA medicine. (Ionis Pharmaceuticals Press Release) - "ION775 achieved substantial, durable and sustained reductions in apoC-III and fasting triglycerides with favorable safety and tolerability in healthy volunteers with moderately elevated triglycerides. Ionis is on track to initiate a Phase 2 study in 2026."

New P2 trial • P1 data • Severe Hypertriglyceridemia